share_log

EF Hutton Reiterates Buy on Lantern Pharma, Maintains $11 Price Target

Benzinga ·  Aug 10, 2023 19:16

EF Hutton analyst Michael King reiterates Lantern Pharma (NASDAQ:LTRN) with a Buy and maintains $11 price target.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment